Ketamine Therapy

Psychedelic-Assisted Therapy, or PAT, is the type of treatment in which the delivery of a psychedelic substance -i.e. ketamine, MDMA, psilocybin, DMT- is regularly paired with psychotherapy by a trained therapist to help produce long-lasting effects in individuals suffering from an ample array of...

Silo Pharma Inc. (NASDAQ: SILO) has agreed with Columbia University to an extension of the psychedelics biotech company's option to license certain treatments currently under development, including Alzheimer’s disease and stress-induced anxiety. The compounds being...

(Part four of a four-part series - Read part three) The reason why companies offering psychedelic-assisted therapy only use ketamine is that at the moment it is the only one that holds a medical license. While psilocybin and MDMA are showing enormous promise, they are still in ...

(Part two of a four-part series, see part one here) Dr. Ben Sessa, cofounder and head of psychedelic medicine at Awakn Life Sciences (OTC: AWKNF) explained that scientific evidence shows ketamine creates neurogenesis: “You actually have growth of nervous tissue. You can...

(Part one of a four-part series) The use of psychedelic-assisted psychotherapy for the treatment of mental health conditions has become a hot topic, with a growing general sense of acceptance, public discussion and reform. Each compound is proven to have specific characteristics,...

Legal ketamine-assisted therapy for people with diagnosed mental health conditions continues to expand throughout the U.S. and Canada.  Numinus Wellness Inc. (OTCQX: NUMIF) announced the opening of a second Canada-based clinic in a week offering several therapy modalities for the...

Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company focused on addiction treatments, has signed a licensing partnership agreement with US ketamine therapy clinics owner Revitalist Lifestyle and Wellness Ltd. (OTCQB: RVLWF), through which Revitalist will treat patients suffering from...

Is At-Home Ketamine Treatment Safe For Patients? A new clinical study of sublingual ketamine telehealth is adding data to the notion that at-home ketamine treatments can be safe and effective for moderate to severe cases of anxiety and depression.  The study was conducted by psychiatrists...

Ehave, Inc. (OTC Pink: EHVVF), a healthcare company developing digital solutions in the medical cannabis and mental health sectors, reported that its wholly-owned subsidiary, KetaDASH, is offering in-home ketamine therapy to patients suffering from treatment-resistant mental health issues. As...

Pasithea Therapeutics Corp. (NASDAQ: KTTA), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced on Wednesday that its wholly-owned subsidiary, Pasithea Clinics, commenced clinical operations,...

Myconic Capital Corp. (CSE: MEDI) agreed to buy Mindscape Ketamine & Infusions Therapy PLLC for $175,000. The investment company, which previously operating as Auralite Investments Inc. and has holdings in cannabis, signed a letter of intent to acquire all shares of Mindscape for...